Clinical Trial

Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma

Study acronym: NEOBLAST
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn about the efficacy and safety of neoadjuvant adebrelimab plus etoposide and cisplatin in patients with neuroendocrine bladder carcinoma. The main questions it aims to answer are: * The pathologic complete response rate at radical cystectomy * Safety and tolerability of combination therapy Participants will be treated with a combination therapy of adebrelimab, etoposide, and cisplatin before radical cystectomy, with a maximum of 4 cycles.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-10-14; most recent amendment 2025-12-02.
Status change: Not Yet Recruiting → Recruiting 2023-11-15
Trial Details
NCT Number NCT06091124
Lead Sponsor RenJi Hospital
Conditions Neuroendocrine Carcinoma of the Bladder, Bladder Cancer
Enrollment 22 participants
Start Date 2023-11-16
Primary Completion 2027-01-01 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-08